Radiotherapy for patients with completely resected pathologic IIIA(N2) non–small-cell lung cancer: a retrospective analysis

References

• Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111(6):1710–1717. doi:10.1378/chest.111.6.17109187198
   PubMed Web of Science ®Google Scholar
• Goya T, Asamura H, Yoshimura H, et al. Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer. 2005;50(2):227–234. doi:10.1016/j.lungcan.2005.05.02116061304
   PubMed Web of Science ®Google Scholar
• Sawabata N, Miyaoka E, Asamura H, et al. Japanese lung cancer registry study of 11,663 surgical cases in 2004: demographic and prognosis changes over decade. J Thorac Oncol. 2011;6(7):1229–1235. doi:10.1097/JTO.0b013e318219aae221610521
   PubMed Web of Science ®Google Scholar
• Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990;323(14):940–945. doi:10.1056/NEJM1990100432314032169587
   PubMed Web of Science ®Google Scholar
• Dillman RO, Herndon J, Seagren SL, Eaton WL Jr. , Green MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst. 1996;88(17):1210–1215. doi:10.1093/jnci/88.17.12108780630
   PubMed Web of Science ®Google Scholar
• Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005;23(25):5883–5891. doi:10.1200/JCO.2005.55.40516087941
   PubMed Web of Science ®Google Scholar
• Lei T, Xu XL, Chen W, Xu YP, Mao WM. Adjuvant chemotherapy plus radiotherapy is superior to chemotherapy following surgical treatment of stage IIIA N2 non-small-cell lung cancer. Onco Targets Ther. 2016;9:921–928. doi:10.2147/OTT.S9551726966380
   PubMed Web of Science ®Google Scholar
• PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet. 1998;352(9124):257–263. 9690404
   PubMed Web of Science ®Google Scholar
• Group PM-aT. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Syst Rev. 2005;9(2):CD002142.
   Google Scholar
• Burdett S, Rydzewska L, Tierney JF, Fisher DJ, Group PM-aT. A closer look at the effects of postoperative radiotherapy by stage and nodal status: updated results of an individual participant data meta-analysis in non-small-cell lung cancer. Lung Cancer. 2013;80(3):350–352. doi:10.1016/j.lungcan.2013.02.005
   PubMed Web of Science ®Google Scholar
• Douillard JY, Rosell R, De Lena M, et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Int J Radiat Oncol Biol Phys. 2008;72(3):695–701. doi:10.1016/j.ijrobp.2008.01.04418439766
   PubMed Web of Science ®Google Scholar
• Robinson CG, Patel AP, Bradley JD, et al. Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base. J Clin Oncol. 2015;33(8):870–876. doi:10.1200/JCO.2014.58.538025667283
   PubMed Web of Science ®Google Scholar
• Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009;136(1):260–271. doi:10.1378/chest.08-097819584208
   PubMed Web of Science ®Google Scholar
• Feng W, Zhang Q, Fu XL, et al. The emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume. BMC Cancer. 2015;15:348. doi:10.1186/s12885-015-1584-325934006
   PubMed Web of Science ®Google Scholar
• Trodella L, Granone P, Valente S, et al. Adjuvant radiotherapy in non-small cell lung cancer with pathological stage I: definitive results of a phase III randomized trial. Radiother Oncol. 2002;62(1):11–19. 11830308
   PubMed Web of Science ®Google Scholar
• Higgins KA, Chino JP, Berry M, et al. Local failure in resected N1 lung cancer: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys. 2012;83(2):727–733. doi:10.1016/j.ijrobp.2011.07.01822208965
   PubMed Web of Science ®Google Scholar
• Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon J-P, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350(4):351–360. doi:10.1056/NEJMoa03164414736927
   PubMed Web of Science ®Google Scholar
• Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352(25):2589–2597. doi:10.1056/NEJMoa04362315972865
   PubMed Web of Science ®Google Scholar
• Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7(9):719–727. doi:10.1016/S1470-2045(06)70804-X16945766
   PubMed Web of Science ®Google Scholar
• Zou B, Xu Y, Li T, et al. A multicenter retrospective analysis of survival outcome following postoperative chemoradiotherapy in non-small-cell lung cancer patients with N2 nodal disease. Int J Radiat Oncol Biol Phys. 2010;77(2):321–328. doi:10.1016/j.ijrobp.2009.05.04419775829
   PubMed Web of Science ®Google Scholar
• Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol. 2006;24(19):2998–3006. doi:10.1200/JCO.2005.04.611016769986
   PubMed Web of Science ®Google Scholar
• Mayer R, Smolle-Juettner FM, Szolar D, et al. Postoperative radiotherapy in radically resected non-small cell lung cancer. Chest. 1997;112(4):954–959. doi:10.1378/chest.112.4.9549377958
   PubMed Web of Science ®Google Scholar
• Bekelman JE, Rosenzweig KE, Bach PB, Schrag D. Trends in the use of postoperative radiotherapy for resected non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;66(2):492–499. doi:10.1016/j.ijrobp.2006.04.03216814952
   PubMed Web of Science ®Google Scholar
• Corso CD, Rutter CE, Wilson LD, Kim AW, Decker RH, Husain ZA. Re-evaluation of the role of postoperative radiotherapy and the impact of radiation dose for non-small-cell lung cancer using the National Cancer Database. J Thorac Oncol. 2015;10(1):148–155. doi:10.1097/JTO.000000000000040625325781
   PubMed Web of Science ®Google Scholar
• Koh Y, Jang B, Jeon YK, et al. EGFR gene copy number gain is related to high tumor SUV and frequent relapse after adjuvant chemotherapy in resected lung adenocarcinoma. Jpn J Clin Oncol. 2011;41(4):548–554. doi:10.1093/jjco/hyq24821247966
   PubMed Web of Science ®Google Scholar
• Ragusa M, Vannucci J, Ludovini V, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients. Am J Clin Oncol. 2014;37(4):343–349. doi:10.1097/COC.0b013e31827a7e7a23357969
   PubMed Web of Science ®Google Scholar